NTD ConnectOR ~ Advanced search
Side-by-side comparison of village-based sampling for Skin snip MF vs. Ov16 ELISA
To compare skin snip microfiladermia with antibody responses against Ov16 antigen in general population in epidemiological assessments post CDTi.
Field evaluation of two schistosome antibody-based rapid tests at point-of-care for prevalence mapping of urinary schistosomiasis in The Gambia
CCA Protocol: To know the sensitivity and specificity of POC CCA in the detection of urinary schistosomiasis, as compared to traditional diagnostic tools.
Field validation of sampling strategies for integrating STH surveys into Transmission Assessment Surveys (Ghana)
Test STH-TAS,Understand the age prevalence of LF Antibody in different setting.
Multi-country perspective on mobile data collection
SCORE Data Collection on Mobile Devises
Snail control in Kenya with 20 year follow-up
Snail Control follow-up study of P. clarkii 20 years later
Analysis of schistosomiasis diagnostics
Human Diagnostics Tool Development (CAA diagnostic tool)
Cross-country analysis of CCA test for screening/mapping
POC/CCA screening/mapping tool initial Studies
Identifying CCA testing standards in Kenya
POC/CCA tool ongoing studies: Use of testing standards; reader differences; ‘Trace’ result analyses
Cost-effectiveness analysis of schistosomiasis control
Cost Studies in SCORE Gaining and Sustaining
Identifying schistosomiasis genetic markers in Brazil
Develop genetic markers for S. haematobium
Schistosomiasis population genetics in Niger and Tanzania
Schistosome Population Genetics in Gaining Control Studies in Niger (Sh) and Tanzania (Sm)
Gaining schistosomiasis control in Kenya, Mozambique, and Tanzania
Gaining Control: >25% Prevalence MDA strategies; and subtle morbidity of Cohort; Population genetics, and snail monitoring
Sustaining and gaining schistosomiasis control in Niger
Sustaining / Gaining Control with Single versus Double Treatment; and Population genetics, snail monitoring
Sustaining schistosomiasis control in Cote D'Ivoire and Kenya
MDA strategies: Sustaining control at 10 – 24% prevalence
Schistosomiasis elimination in Zanzibar
(1) Is it possible to eliminate schistosomiasis as a public health problem on Unguja in three years and to interrupt transmission in five years? (2) Is it possible to control schistosomiasis throughout Pemba (prevalence <10%) in three years and to eliminate it as a public health problem in five years? (3) What are the costs, successful strategies, barriers, etc. associated with three different interventions (MDA, vector control, and behavior change)?
Randomized trial of Ivermectin/Albendazole vs. Ivermectin alone
Randomized clinical trail comparing treatment with Albendazole and Ivermectin to Ivermectin alone for Onchocerciasis.
Randomized trial of albendazole alone for LF in Cote d'Ivoire
Randomized Clinical Trial of Albendazole vs Ivermectin+Albendazole for lymphatic filariasis treatment and elimination.
Randomized trial of triple therapy (DEC/Alb/Iver) in Papua New Guinea
Randomized Clinical Trial comparing triple triple therapy of DEC/Alb/Iver vs. DEC/Alb alone
Analysis of MDA frequency and Brugia in Indonesia
Comparison of 2X vs. 1X per year MDA on Brugia with MDA of DEC/Alb , plus STH evaluation
Analysis of MDA for LF in loa endemic countries
Community MDA with 2X Alb alone for W. bancrofti in areas co-endemic for L. loa, plus STH evaluation
Comparison of Filariasis Binax Test and Alere Test Strip
Binax Now Filariasis Test vs. Alere Filariasis Test Strip Comparison
Analysis of MDA frequency in Liberia and Cote D'Ivoire
Comparison of 2X vs. 1X per year MDA on W. bancrofti with MDA of IVM/Alb, plus STH evaluation (and Schistosoma in Foya only)
Analysis of MDA frequency in Indonesia and Papua New Guinea
Comparison of 2X vs. 1X per year MDA, W. bancrofti with MDA of DEC/Alb, plus STH evaluation